The Limits of Collaborative Care: Why the CLARO Trial Found No Added Benefit for OUD and Comorbid Mental Illness

MedXY Editorial Team•Jan 1, 2026•Internal Medicine

The CLARO trial found no significant difference between collaborative care and enhanced usual care (EUC) regarding time to buprenorphine initiation or cumulative days of medication for opioid use disorder (MOUD).
Mental health outcomes, measured by PHQ-9 (depression) and PCL-5 (PTSD) scores, improved in both the intervention and control groups, with no statistically significant advantage for the collaborative care arm.
The intervention utilized community health workers (CHWs) as care managers in low-resource primary care settings, highlighting the difficulties of managing high-acuity patients with multi-faceted biopsychosocial needs.
Spillover effects and spontaneous improvement within the control group may have narrowed the gap between the two study arms.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

The CLARO trial found no significant difference between collaborative care and enhanced usual care (EUC) regarding time to buprenorphine initiation or cumulative days of medication for opioid use disorder (MOUD).
Mental health outcomes, measured by PHQ-9 (depression) and PCL-5 (PTSD) scores, improved in both the intervention and control groups, with no statistically significant advantage for the collaborative care arm.
The intervention utilized community health workers (CHWs) as care managers in low-resource primary care settings, highlighting the difficulties of managing high-acuity patients with multi-faceted biopsychosocial needs.
Spillover effects and spontaneous improvement within the control group may have narrowed the gap between the two study arms.